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ABSTRACT
Background: Intention­to­treat analysis is used in the analysis of randomized controlled trials to preserve trial power in the
presence of missing subject data as well as to control for both known and unknown confounding factors. One form of intention­
to­treat analysis is last­observation­carried­forward (LOCF). Concerns exist regarding whether it is appropriate to use LOCF in
analyses involving progressive conditions or in situations where missing data are nonrandom (e.g., subjects drop out because of
treatment side effects or differing disease severity).
Objective: To examine the use of intention­to­treat imputation of missing data techniques, and specifically LOCF, in random­
ized controlled trials of the use of cholinesterase inhibitors and memantine to treat Alzheimer’s disease, vascular dementia,
mixed dementia and mild cognitive impairment.
Methods: We conducted a systematic electronic search of MEDLINE and the Cochrane Central Register of Controlled Trials
from 1984 to 2008 for double­blinded, randomized controlled trials of cholinesterase inhibitors or memantine that examined
progressive symptoms in Alzheimer’s disease, vascular dementia, mixed dementia and mild cognitive impairment. We collected
data on the use of intention­to­treat and non­intention­to­treat analyses and on contraindications to the use of LOCF analysis
and we performed quality assessments of included trials.
Results: Of the 57 studies that met the inclusion criteria, 12 did not report intention­to­treat analyses. Of the 34 studies that em­
ployed LOCF as the only form of intention­to­treat analysis, 24 reported conditions that could produce biased LOCF analyses fa­
vouring the drug under study. The latter finding was more common in cholinesterase inhibitor trials than in memantine studies.
Conclusions: The published results of some randomized controlled trials of dementia drugs may be inaccurate (i.e., drug effect­
iveness may be exaggerated) or invalid (i.e., there may be false­positive results) because of bias introduced through the inappro­
priate use of LOCF analyses. This bias favours cholinesterase inhibitors, potentially preventing funding of and patient access to
less toxic treatment options such as memantine. Licensing agencies should consider whether to accept LOCF analyses in re­
search on dementias and other chronic progressive conditions.
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I
T IS ESTIMATED THAT 24.3 MILLION PEOPLE WORLD­
wide suffer from dementia and that annual costs for
Alzheimer’s disease are as high as $155 billion in
the United States (1996 US dollars).
1,2 One potential
way to decrease the negative impact of dementia on
people with this condition, on their families and on soci­
eties is to optimize the use of dementia medications,
2
with due consideration of both their effectiveness and
their toxicity.
The effectiveness of most medications is tested via
randomized controlled trials (RCTs). It is inevitable that
some participants drop out of such studies before they
are completed. Unfortunately, if analyses include only
participants who remain in the trial, then study power
is lost and erroneous conclusions may be generated.
The principle of intention­to­treat (ITT) analysis, in
which all patients are included in the analysis according
to the group to which they were assigned at randomiza­
tion, has become the accepted standard for the analysis
of RCTs to try to counteract this problem.
3 The strength
of ITT analysis is that it not only preserves power but
also promotes balance between treatment groups for
both known and unknown confounders, thereby pre­
serving the benefits of randomization.
Ideally, all possible data are collected on all subjects,
including those who drop out of the study; however,
this is not always possible. In order for ITT approaches
to analyze all patients randomly assigned to a group,
several methods to impute missing data have been de­
veloped.
3­10 Unfortunately, no statistical strategy can
deal fully with all the different combinations of reasons
for dropping out, dropout rates and different disease
courses. At best, these techniques to impute missing
data are educated estimates. One commonly employed
technique to impute missing data is last­observation­
carried­forward (LOCF), also known as end­point ana­
lysis.
LOCF substitutes subjects’ missing outcomes with
the last measurement taken before they dropped out. It
requires that 2 basic assumptions be met: the subjects’
responses would have been constant from the last ob­
served value (i.e., the point at which they dropped out)
to the end point of the trial; and, missing values are
missing completely at random (i.e., dropout is not re­
lated to variables such as drug side effects, group as­
signment, disease severity or symptoms).
5­7
Authors have highlighted 3 factors that cause the
second condition to be breached in a manner that intro­Research Molnar et al
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duces bias that will exaggerate the effectiveness of treat­
ments as estimated by LOCF analyses; these include
earlier dropouts or greater dropout rates in the treat­
ment group and more rapid disease progression in sub­
jects who drop out of the treatment group.
3,4,9­11 These
factors result in more subjects who drop out of the treat­
ment group having their decline artificially frozen at an
earlier stage of disease, thereby potentially biasing res­
ults in favour of the drug under study (i.e., overestimat­
ing effectiveness relative to the placebo). By extension,
study results may also be biased against the drug under
study (i.e., underestimating effectiveness) if there are
earlier dropouts or greater dropout rates in the control
group or if there are subjects whose disease progresses
more rapidly among those who drop out of the control
group (Figures 1 and 2).
Since 1998, researchers have expressed concern that
the use of LOCF in dementia drug trials contravenes the
assumption of disease stability and the assumption of
random missing data and hence risks generating biased
results.
2,11­21 To better understand the significance of
these concerns in dementia research we systematically
reviewed the use of ITT and LOCF analyses, contraindic­
ations to the use of LOCF analysis, and the use of non­
ITT analyses in RCTs of drugs approved for the treat­
ment of Alzheimer’s disease, vascular dementia, mixed
dementia and mild cognitive impairment in Canada
(i.e., cholinesterase inhibitors such as donepezil,
rivastigmine and galantamine, and the N­methyl­D­as­
partate (NMDA) receptor antagonist memantine).
Methods
We performed an electronic literature search of MED­
LINE and the Cochrane Central Register of Controlled
Trials from January 1984 (the year of publication of the
McKhann criteria for Alzheimer’s disease
22) to February
2008 using the OVID search interface. The search
strategy included the following terms: randomized con­
trolled trials, dementia, Alzheimer, vascular dementia,
mixed dementia, donepezil, Aricept, rivastigmine, Ex­
elon, galantamine, Reminyl, memantine, Ebixa and
cholinesterase inhibitor.
The principal investigator reviewed titles and ab­
stracts to select an overly inclusive list of potential art­
icles to be subjected to a full review of text and
reference sections to identify relevant RCTs. The fullResearch Molnar et al
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text of selected RCT reports was then independently re­
viewed by 2 certified specialists in geriatric medicine
with clinical expertise in dementia, formal research
methodological training and recognized expertise in the
review of dementia drug trials to determine which RCT
reports met the inclusion criteria for the systematic re­
view.
Inclusion criteria. We included double­blinded, ran­
domized controlled trials of cholinesterase inhibitors or
memantine that examined progressive symptoms (e.g.,
cognition, function) in Alzheimer’s disease, vascular de­
mentia, mixed dementia or mild cognitive impairment
and that employed DSM­IV (Diagnostic and Statistical
Manual of Mental Disorders)
23 or NINCDS–ADRDA
(National Institute of Neurological and Communicative
Disorders and Stroke – Alzheimer’s Disease and Re­
lated Disorders Association)
22 criteria for Alzheimer’s
disease or NINDS–AIREN (National Institute of Neuro­
logical Disorders and Stroke – Association Interna­
tionale pour la Recherche et l’Enseignement en
Neurosciences) criteria for vascular dementia. Trials of
cholinesterase inhibitors not currently licensed in
Canada (tacrine, metrifonate) were not reviewed. The
systematic review was restricted to studies with full trial
reports published in English­language peer­reviewed
journals. The diagnostic criteria for mild cognitive
impairment were not specified, as they were in develop­
ment when the relevant studies were published.
Although the reference sections of open­label stud­
ies, reviews, meta­analyses, commentaries, editorials,
studies of pooled data from previous studies and toler­
ability and safety studies were searched for relevant
RCTs, the articles themselves were not included in the
systematic review. Subgroup analyses and secondary or
retrospective analyses were also excluded.Research Molnar et al
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Data collection. Data collected included publication de­
tails, investigative site locations, funding, drug compar­
ators, drug doses, diagnostic criteria employed, type(s)
of analysis employed, discussion of the limitations of
the forms of analysis employed, dropout characteristics
(e.g., number, timing, patient characteristics, reasons
for dropout), contraindications to the use of LOCF and
the results of each study’s primary and secondary out­
come measures.
The 2 previously mentioned reviewers independ­
ently extracted data from all included studies and then
met to review their findings and discuss discrepancies.
When consensus could not be achieved, discrepancies
were forwarded to a third party for independent review.
Results
Of the 1146 articles identified by the search strategies,
191 papers (including RCT reports, reports of nonran­
domized trials, commentaries, systematic reviews and
meta­analyses) were selected for full text and reference
section review. Of these, 57 RCT reports met the eligibil­
ity criteria for systematic review (Fig. 3).
2,14,20,21,26­79
Reviewer agreement. Although agreement on abstrac­
ted items was not formally measured, the methods em­
ployed resulted in consensus on almost all abstracted
items. After the reasons for different ratings were ex­
plained (differences were mostly a result of difficulty
finding the relevant data in the studies reviewed), the re­
viewers agreed on all but 5 final ratings. These were ar­
bitrated by a third party. The kappa score, if it had been
measured, would have been unusually high.
Trial characteristics. Details of the 57 included trials
are provided in Tables 1 and 2. Forty­five studies en­
rolled patients with Alzheimer’s disease (21 involved
donepezil, 11 rivastigmine [1 of these studies was a
donepezil–rivastigmine comparison study], 7 galantam­
ine and 6 memantine), 8 studies enrolled patients with
vascular dementia or mixed dementia (3 involved
donepezil, 3 galantamine and 2 memantine) and 4 stud­
ies enrolled patients with mild cognitive impairment (2
involved donepezil, 1 rivastigmine and 1 galantamine).
In 40 trials there was an explicit statement of phar­
maceutical industry funding. In 6 trials industry fund­
ing was implied (the authors were pharmaceutical
industry employees but the source of funding was not ex­
plicitly stated). Three studies were funded by industry
in partnership with public funders, and 4 studies were
entirely publicly funded (Table 1). The source of funding
for 4 studies could not be determined. All 57 study re­
ports were rated as demonstrating high­quality method­
ology with a Jadad–Schultz score greater than or equal
to 3 (Table 1).
Reporting of dropouts. Data on dropouts are provided
in Tables 3 and 4. Dropouts were described in 94% of
cholinesterase inhibitor studies and 100% of
memantine trials. Seven of the 49 cholinesterase inhib­
itor trials (14%) and none of the memantine trials re­
ported data on the timing of dropouts. The reasons for
dropout were often difficult to discern, as many were
described as adverse events that might have been due to
drug side effects but were not reported as such. Cholin­
esterase inhibitor studies were more likely than
memantine studies to demonstrate a higher dropout
rate in the treatment group than in the control group
(73% of cholinesterase inhibitor studies v. 25% of
memantine studies). When cholinesterase inhibitor
studies were combined there was a higher dropout rate
in the treatment group than in the control group (23.2%
in the treatment group v. 16.8% in the control group)
(Table 4). When memantine trials were combined the
opposite pattern was noted: there were fewer dropouts
in the treatment group than in the control group (14.6
% in the treatment group v. 18.5% in the control group)
(Table 4). Ten studies (18%) discussed potential bias as­
sociated with dropouts.
Types of non‐ITT analyses conducted. The most com­
mon non­ITT analysis (employed in 35 trials) was ob­
served case analysis (Table 2). Other forms of non­ITT
analysis included fully evaluable population analysis (5
RCTs), treatment per protocol analysis (5 RCTs) and
completer analysis (3 RCTs) (Table 2).
Types of ITT analyses conducted. Twelve (21%) of the
57 studies did not identify the type of analysis per­
formed (5 studies) or performed only non­ITT analysis
(7 studies) (Table 2). Of the 45 studies in which an iden­
tifiable form of ITT analysis was performed, 42 (93%)
employed LOCF (Table 2). Thirty­four of the trials in
which ITT analysis was performed (76%) relied on
LOCF as the only form of ITT analysis (Table 2).
Ten of the 57 studies (17.5%) reported employing
ITT techniques other than LOCF (Table 2); 6 of 49
cholinesterase inhibitor studies (12%) and 4 of 8
memantine studies (50%) employed ITT techniques
other than LOCF. The 6 alternative approaches for ITT
imputation of missing data included the following: re­
placement of missing values with the mean changes ob­
served in the placebo group;
42,58 time­response
relationship for change in ADAS­cog/11 (the Alzheimer
Disease Assessment Scale – Cognitive Subscale 11­item)
score analyzed using generalized linear modelling;
50,52
mixed­effects modelling;
56,63 mixed­models repeated
measures;
78,79 replacement of missing data with worst
ranks;
57 and sensitivity analyses consisting of a number
of simulations.
68
Of the 42 studies employing LOCF, only 8 reported
performing another type of ITT analysis to confirm theResearch Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al.
Open Medicine 2009 3(2):31-50Research Molnar et al
Open Medicine 2009 3(2):31-50
results. In 3 of these 8 studies the authors did not com­
ment on the results of the alternative non­LOCF ITT
analysis. In 4 of the 5 studies in which the authors com­
mented on the results of the alternative ITT analysis,
they did not report the values calculated by this analysis
but they did indicate that the direction of the results
was unchanged. It is uncertain whether the point estim­
ates of the outcomes were similar when the alternative
ITT analyses were performed.
In only 1 study were the point estimates of outcomes
measuring drug efficacy generated by LOCF verified
with point estimates generated by an alternative form of
ITT analysis.
42 The values of 3 positive outcomes were
verified in this study.
Contraindications to the use of LOCF as the only
form of ITT analysis. Of the 34 studies employing
LOCF as the only form of ITT analysis, 24 (71%) expli­
citly demonstrated contraindications (factors that could
introduce bias) to its use. It was unclear whether the re­
maining 10 studies were free of contraindications, be­
cause most studies failed to report adequate data
regarding the timing of dropouts and the severity of dis­
ease of the participants who dropped out. Con­
sequently, Table 2 provides a range of potential
contraindications to the use of LOCF for each study (the
lower number representing the number of explicitly
identified contraindications). Seven of the 57 trials in
this review (12%) discussed the limitations of LOCF or
non­ITT approaches.
Discussion
Despite previously published cautions that LOCF ana­
lysis may introduce bias into dementia research, LOCF
remains the most widely employed analytic technique
in this research area; its results are rarely verified by
other forms of ITT analysis. Further, the majority of the
publications reviewed in the present study did not re­
port the results of an ITT analysis, did not verify the
results of LOCF with alternative ITT analyses when
conditions that could introduce LOCF analytic bias in
favour of the study drug existed, or did not comment on
the results of alternative ITT analyses that were per­
formed.
These problems were particularly evident in cholin­
esterase inhibitor trials. In the majority of these trials,
either no ITT results were provided or LOCF ITT ana­
lysis was performed in the presence of contraindicating
factors. For example, a higher dropout rate in the treat­
ment group than in the control group was more com­
mon in cholinesterase inhibitor studies than in
memantine studies (73% v. 25%), potentially biasing
study results in favour of cholinesterase inhibitors and
against memantine. Owing to a lack of data on the tim­
ing of dropouts and on the severity of disease in study
participants who dropped out, our results may in fact
underestimate the true prevalence of conditions pro­
moting bias.
The concern that LOCF analysis introduces bias can
be explored via ITT sensitivity analyses. If similar out­Research Molnar et al
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comes are generated when other forms of ITT analysis
are employed, this provides some reassurance (but does
not guarantee) that LOCF analytic bias does not alter
results. Only 1 study verified the point estimates of effic­
acy calculated by LOCF analysis with an alternative ITT
analysis.
42 The 3 positive point estimates verified by al­
ternative ITT analyses in this study are the only ones
out of the hundreds of positive outcomes reported for
LOCF analyses in dementia trials to have been verified
in this way.
Some may erroneously argue that results of previous
studies have been adequately confirmed by non­ITT ana­
lyses (i.e., techniques that exclude subjects without data
from analysis), such as observed case analysis, completer
analysis, fully evaluable population analysis or treated­
per­protocol analysis. Like LOCF analysis, these non­ITT
techniques may be systematically biased in favour of the
group with greater, earlier or more severely affected dro­
pouts and, consequently, they are not reliable, valid sensit­
ivity analyses. The biases inherent in these non­ITT
techniqueshavebeenhighlightedbytheInternationalCon­
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use,
80 by the
European Agency for the Evaluation of Medicinal
Products
14 and by a number of authors.
15,53,67,81
Furthermore, the use of such non­ITT techniques
and of LOCF analysis is completely unnecessary: other
forms of ITT analysis that do not treat dropouts artifi­
cially by freezing values at the point of dropout but
rather model for expected natural decline in dropouts
could easily be performed either as the primary analysis
or as a sensitivity analysis. The available approaches
range from techniques that simply apply the rate of de­
cline noted in the control group to all dropouts to more
complex modelling procedures that are available in
standard statistical programs. More appropriate forms
of analysis have been employed in dementia re­
search.
42,50,52,56­58,68,78,79 Petersen’s study of mild cognitive
impairment
68 may serve as a model for future research,
as it employs both modelling for dropouts and sensitiv­
ity analyses of the effect of various modelling assump­
tions and approaches.
The present study cannot quantify the magnitude of
the effect of the use of LOCF analysis on trial results; it
is restricted to highlighting the high prevalence of condi­
tions promoting bias in favour of more toxic therapies
and against less toxic alternatives, such as memantine.
As verification of results obtained using non­ITT and
LOCF analyses requires individual patient data that are
not publicly available, the onus is on the investigators
who publish these trials to disprove the possibility that
these analyses have introduced bias by performing ITT
sensitivity analyses as performed in Petersen’s study of
mild cognitive impairment.
68 This is particularly true
for those studies demonstrating higher dropout rates in
treatment groups.
These results are meaningful in day­to­day clinical
care. Because this bias has likely exaggerated results in
favour of more toxic therapies (e.g., cholinesterase in­
hibitors), this may have created inappropriate barriers
to the funding and prescription of less toxic treatment
options for dementia (e.g., memantine). Without accur­
ate analyses, physicians cannot optimally counsel pa­
tients and families regarding appropriate therapies, and
patients and families cannot provide truly informed
consent when making treatment decisions. In addition,
meta­analyses and pharmacoeconomic studies cannot
be performed accurately and we cannot make reliable
statements regarding whether trial results truly cross
thresholds of clinical significance. These concerns, as
well as the fact that LOCF analytic bias may prevent the
funding and use of future less toxic treatments, should
be of great concern to patient advocacy groups, such as
the Alzheimer Society of Canada and the US
Alzheimer’s Association.
In summary, it is highly unlikely, given the high
prevalence of conditions promoting LOCF analytic
bias in this study, that point estimates of some of
the hundreds of positive outcomes generated in tri­
als have not been affected in some way. The ques­
tion is likely not whether bias been introduced, but
rather the number of outcomes that have been
biased and the degree to which they have been
biased. As such, the present results provide empiric­
al support for recent recommendations to research­
ers, licensing bodies and research guidelines
bodies
82 regarding their use of LOCF analysis. One
of these recommendations is that the CONSORT
group (www.consort­statement.org) consider incor­
porating guidelines regarding appropriate analyses
for studies of medications used to treat chronic pro­
gressive disorders into the CONSORT Statement so
that journal editors, funding agencies, ethics review
boards and drug formulary committees can request
that these recommendations be followed in future
studies of dementia and other chronic progressive
disorders. In the meantime, researchers should en­
sure that analyses promoting bias are avoided or
scrutinized using alternative ITT sensitivity ana­
lyses. Further, licensing agencies (e.g., the US Food
and Drug Administration, the European Agency for
the Evaluation of Medicinal Products, and Health
Canada) should review this situation immediately to
determine whether they will continue to accept
LOCF analyses in research on dementia and other
chronic progressive conditions.Research Molnar et al
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